SUMMARY In a double-blind, within-patient study, blood pressure was measured at regular intervals at the clinic by the physician and each day at home by the patient. Both methods of blood pressure measurement demonstrated an antihypertensive effect of the diuretics chlorthalidone (25 mg) and triamterene (50 mg) and the /3-blocker oxprenolol (160 mg) and the greater efficacy of the combination of the two therapies. During placebo, as well as during active treatment, blood pressure values were higher at the clinic than at home, except when the patients were taking the /3-blocker, which minimized the arousal response during blood pressure measurements in the clinic. With 2-week treatment periods, separated by 2 weeks of placebo administration, blood pressure returned toward its initial level after each of the three treatments and none of the carryover effects was significant at the 5% level. This methodology was intended to make it possible to demonstrate in 27 patients at the clinic and in 20 patients with measurements made at home, at the usual statistical risks (a = 5%, /3 = 10%), a fall of 5 mm Hg in diastolic blood pressure in comparison with a placebo. Moreover, at the end of this 3-month follow-up, each patient could continue to receive the treatment that was the most effective and the best tolerated. In conclusion, the use of a within-patient trial design, with a 15-day washout period between active treatments and careful recording of blood pressure values, can minimize the number of patients included in hypertension trials and offer to each patient the possibility of individualization of treatment. (Hypertension 11: 153-159, 1988) KEY WORDS • within-patient study • self-recorded blood pressure • antihypertensive trial T HE methodology used to investigate the antihypertensive effect of a drug is well known, and a wide variety of controlled trials have been performed to define the magnitude and the duration of the fall in blood pressure induced by an antihypertensive agent in comparison with a placebo or a reference drug.
T HE methodology used to investigate the antihypertensive effect of a drug is well known, and a wide variety of controlled trials have been performed to define the magnitude and the duration of the fall in blood pressure induced by an antihypertensive agent in comparison with a placebo or a reference drug. 1 However, the more complete description of the fluctuations in blood pressure in day-to-day life that has been provided by continuous ambulatory recordings of blood pressure 2 "* has drawn attention to the fact that different methods of measuring blood pressure, such as ambulatory recordings, home blood pressure measurements, physician's measurements, or recording at rest by automatic devices, can provide different results. 7 ' 8 These observations have renewed interest in the methodological aspects of antihypertensive trials, all the more so since erroneous statistical interpretations have also been pointed out in various published studies. 9 "" Finally, a technique for randomized trials in individual patients ('W of 1" studies) has recently been proposed, 12 and despite the difficulties of such within-patient designs, 13 ' u this technique could be useful in hypertension for individualizing the choice of therapy.
For these reasons we have reanalyzed the data cumulated in one of our previous unpublished trials. The aim of this study was to confirm, in a double-blind, randomized, within-patient study of 24 patients, the generally well-accepted results according to which a /3-blocker is equipotent to a diuretic, when the doses compared are appropriately matched, and the association of the two drugs is more effective in lowering blood pressure than either drug prescribed alone." In the present report, we have reanalyzed our data 1) to verify that the crossover design with washout periods 154 HYPERTENSION VOL 11, No 2, FEBRUARY 1988 used in this trial is appropriate to quantify the antihypertensive efficacy of three different treatments and provides valuable data for calculation of the statistical power of such trials; 2) to compare the results obtained by home blood pressure measurements with those obtained by blood pressure measurements at the clinic; and 3) to examine the possibility of using the results of such a trial to make choices among the three tested treatments at the level of the individual study participants.
Patients and Methods
All the patients (20 men and 4 women) approached were willing to participate in the study, the purpose and design of which were fully explained to them. Their mean age was 50 years (age range 30-62 years). They had essential hypertension (i.e., diastolic blood pressure between 95 and 110 mm Hg on two different visits to the clinic before the study). None had secondary hypertension, complicated hypertension, or contraindications to the prescription of diuretics or )3-blockers. Patients with a suspected coronary insufficiency defined by questioning and by electrocardiograms were not eligible, since the protocol included two interruptions of the /8-blocker treatment.
Protocol
A double-blind, within-patient, crossover study was planned to quantify the antihypertensive effects of oxprenolol (160 mg) once a day, a combination of chlorthalidone (25 mg) and triamterene (50 mg) once a day, and the combination of both diuretics and the 0-blocker (chlorthalidone, 25 mg; triamterene, 50 mg; and oxprenolol, 160 mg). Each patient was exposed successively to all three treatments, and the order of administration was randomized. Each 1-month treatment sequence consisted of 2 weeks of placebo followed by 2 weeks of active treatment. Throughout the study the patients took two tablets in the morning.
Blood Pressure Measurements
For each patient, blood pressure was measured in the morning at the outpatient clinic by the same physician throughout the trial. Blood pressure was measured by the auscultatory method with a mercury sphygmomanometer, after a 5-to 10-minute rest in the sitting position, in the same arm as was used by the patient for home blood pressure measurements. Five successive measurements were made, and the mean of these was taken as the final value. During a 30-minute instruction by the physician in charge of the trial, each patient was shown how to measure his or her blood pressure at home. Practical advice was provided on the appropriate use of the device, and answers were given to the patients' questions on blood pressure measurements and blood pressure regulation.
These patients were taken from a hypertensive population referred to a specialized clinic who responded favorably to a questionnaire completed by 400 successive patients. Results of this survey are shown in Table 1 . The device used for the home blood pressure measurements was a semiautomatic machine (Tonotest, Bosch, France) with a microphone connected to the dial where the values were automatically signaled by two indicators, one for the systolic and the other for the diastolic blood pressure. Blood pressure was measured at home by the patient twice a day, in the morning and in the evening. For each of the three treatment periods, all the calculations were made on the basis of the average of all the values recorded by the patient during the second of the 2 weeks of active treatment. Blood pressure values recorded at home during the second week of placebo administration were analyzed for each of the three placebo periods.
After a first visit, mainly to verify the patient's cooperation and ability to measure his or her own blood pressure, the other visits at the clinic were scheduled on Day 14, after the first period of placebo administration, and then on Days 28, 56, and 84 (i.e., at the end of each period of active treatment). This schedule allowed the patients to come to the hospital, after the first two visits, once a month instead of every 2 weeks, but for this reason the changes in blood pressure for clinic recordings could only be calculated from the first placebo baseline value. Three patients who complained of side effects during the first placebo runin period were excluded from the trial.
The accuracy of the Tonotest was checked during the second visit, after 2 weeks of placebo administration, and during the last visit. Blood pressure was measured five times consecutively by the patient, with the Tonotest, and then five times consecutively by the physician, by the auscultatory method with a mercury sphygmomanometer. At the beginning of the trial, systolic blood pressure was 165 ± 25 mm Hg (mean ± SD) with the Tonotest and 161 ± 20 mm Hg by the auscultatory method (t = 0.58, NS) and diastolic blood pressure was 104 ± 13 and 100 ± 1 1 mm Hg, respectively (r = 1.11, NS). At the end of the trial, systolic blood pressure was 131 ± 16 mm Hg with the Tonotest and 139 ± 14 mm Hg by the auscultatory method (f = 1.88, NS) and diastolic blood pressure was 91 ± 9 and 90 ± 7 mm Hg, respectively (t = 0.23, NS). These evaluations, made at the beginning and at the end of the trial, ensured that the differences observed between the two methods of measurement were not due to a problem peculiar to the semiautomatic device.
Statistical Analysis
All results are expressed as means ± SD. A classic model of variance analysis, derived from the crossover design, was applied to the systolic and diastolic pressures taken by both the patient and the physician. This model allows for patient, treatment, and period effects. Because of the balanced design, each treatment being preceded equally often by each of the other treatments, it was also possible to test for carryover treatment effects. As a consequence, a model allowing for direct and residual treatment effects was used for the blood pressure measurements. 1617 As already mentioned, the changes in blood pressure were calculated from the first placebo baseline value for clinical recordings and from the preceding placebo period for home recordings.
It was also possible to select, for each patient, the most effective of the three treatments, which could then be considered as an individualized therapeutic choice. Two-way comparisons of the antihypertensive effects, between the three treatments and the individual choice, were performed using the Newman-Keuls multiple comparison procedure, with a mean square error derived from the one-way (treatment) analysis of variance.
Results

Trial Results
Changes in Blood Pressure
With recordings in the clinic, the variance analysis showed the absence of period effect both for systolic (F = 1.67, p = 0.2) and diastolic recordings (F = 1.09, p = 0.34) and a treatment effect for systolic (F = 9.99, p < 0.001) and diastolic recordings (F = 8.98, p < 0.001). All three treatments lowered the blood pressure in comparison with placebo in the first period, as shown in Table 2 . The combination of the diuretics and the /3-blocker was more effective than each type of treatment alone. It lowered blood pressure by 23.2 ± 12.7/9.1 ± 8.5 mm Hg, whereas oxprenolol lowered it by 14.3 ± 13.5/7.7 ± 7.2 mm Hg, and chlorthalidone-triamterene lowered it by 13.5 ± 11.1/ 3.0 ± 8.5 mm Hg.
With home recordings, the variance analysis showed the absence of period effect for both systolic (F = 0.40, p = 0.67) and diastolic recordings (F = 0.50, p = 0.61). All three drugs lowered the blood pressure in comparison with placebo (preceding period), as shown in Table 2 . There were no statistically significant differences between the falls in blood pressure induced by the diuretics (8.8 ± 10.7/4.8 ± 6.6 mmHg) and the £-blocker (5.1 ± 1 2 . 3 / 3 . 1 ± 8.6 mm Hg). The combination appeared to be more effective (13.5 ± 12.6/5.7 ± 6.4 mm Hg), but the difference was statistically significant only for the systolic values.
Residual Treatment Effects
It is possible to include in the model carryover treatment effects, that is, the effects observed in Periods 2 and 3, respectively, of the treatment applied in the preceding treatment Periods 1 and 2, respectively. None of the carryover effects was significant at the 5% level. However, for clinic recordings and systolic home recordings, the analysis showed carryover effects at the 10% level. Since this can be considered weak evidence of carryover effects, one can adjust for residual effects, as advocated by Abeyasekera and Curnow.
l7 Adjusted treatment effects appear in Table 2 and are only slightly different from the unadjusted means.
Methodological Observations Comparison of Blood Pressure Recordings at Home and in the Clinic During the Three Active Treatment Periods
The systolic blood pressure values over the three treatment periods measured by both methods were significantly correlated (r = 0.62, p < 0.001, n = 72), as were the diastolic blood pressure values (r = 0.65, p < 0.001, n = 72). However, when the statistical method discussed by Bland and Altaian 9 for assessing agreement between two methods of clinical measurement was used, the estimated limits of agreement at the 95% level were very wide, from -29.3 to + 18.7 mm Hg for the systolic blood pressure (clinic blood pressure -home blood pressure = -6 . 2 ± 12.8 mm Hg), and from -13.9 to + 14.9 mm Hg for diastolic blood pressure (clinic blood pressure -home blood pressure = -0.5 ± 7.2 mm Hg).
During the first placebo period, systolic recordings in the clinic were higher than those recorded at home (154 ± 13vsl43 ± 15mmHg;r = 3.86,/? < 0.01). They were also higher during the diuretic treatment (141 ± 13vsl33 ± 12mmHg;r = 3 . 4 2 , p < 0.01). The differences for diastolic recordings were never statistically significant. On the other hand, during treatment with the /3-blocker and with the /3-blocker and diuretics combined, neither the systolic nor the diastolic blood pressure recordings showed significant differences between the home and clinic measurements, although there was a trend for higher recordings of the systolic blood pressure at the clinic (see Table 2 ).
Changes in Blood Pressure During the Placebo Period
The variance analysis of the blood pressure values measured during the last week of each of the three 2-week placebo periods (Weeks 2, 6, and 10 of the trial) did not show any significant difference (F = 3.11, p = 0.06 for systolic blood pressure; F = 0.11, p = 0.90 for diastolic blood pressure; active treatment with a placebo, blood pressure measured at home returned toward its initial level.
Sensitivity of the Trial
The sensitivity of such a design can be described by its statistical power (i.e., the probability of detecting a difference between two treatments when such a difference exists). The power curves of this trial have been drawn for falls in systolic and diastolic blood pressure, measured by the patient and by the physician ( Figure  1 ). These curves reflect less dispersion of the data when using home blood pressure measurements. However, as shown earlier, the therapeutic effect was greater when physician's blood pressure measurements were used. These two phenomena affect the sensitivity of the trial in opposite directions. Nevertheless, the curves show that, with 24 patients, at a two-sided a risk of 5%, this methodology has more than an 80% chance of detecting a 5 mm Hg change in diastolic blood pressure and a 10 mm Hg change in systolic blood pressure, whatever method of measurement is used. 
Indtvidualization of the Treatment of Choice
Although these patients were exposed to each treatment for only one 15-day period, the choice of therapy could be made for the individual patient on the basis of the greatest fall in blood pressure induced by one of these treatments. A fall of more than 5 mm Hg in the diastolic blood pressure measured at the clinic can be considered the minimum clinically relevant fall that one can expect from the prescription of an antihypertensive agent. According to this criterion, in three patients none of the treatments was effective. The diuretics were the most effective treatment in four patients, the /3-blocker in seven, and the combination in 10. In Table 4 , the average falls in blood pressure induced by the three possible strategies (i.e., systematic prescription of the diuretics, the /3-blocker, or the combination) are compared with the individual choice. The one-way analysis of variance showed a highly significant treatment effect, with the exception of the diastolic blood pressure measured at home.
In no instance could the results of the individual choice be distinguished from the results of the combination when 2 x 2 comparisons were performed, but it was always better (p < 0.01) than the monotherapy for the fall in systolic and diastolic blood pressures measured at the clinic and better than the /3-blocker (p < 0.01) for the fall in systolic blood pressure measured at home. These data suggest that this individual choice of treatment would have the same antihypertensive effect as the systematic prescription of a combination, but it would minimize the number of ingested active drugs in more than half of the patients.
Discussion
The stepped-care treatment programs that were recommended up to 1985 for the treatment of essential hypertension usually considered diuretics and /3-blocker equivalents as a first-step treatment. 18 Indeed, their antihypertensive effect is very similar, even if slight differences have been reported in favor of one or the other, which could be due to the choice of the dose of the diuretic or the /3-blocker or to the race, age or renin status of the group of patients studied. 19 It is also well demonstrated that the association of a diuretic and a /3-blocker induces a greater fall in blood pressure than either compound alone, although this fall may not be as great as the sum of the individual falls." Therefore, the blood pressure results of this trial, performed in 1979 and 1980, are merely a confirmation of the evidence from the medical literature during the last few years. 13 The changes in body weight, heart rate, plasma potassium, plasma uric acid, and plasma renin activity, not reported here, were consistent with the known biological effects of the treatment and confirmed that the study was performed according to the protocol without major problems of patient compliance.
The purpose of this report was to validate several aspects of the methodology chosen for this clinical trial and to outline its advantages for the patients who agreed to participate in this time-consuming study. These observations provide interesting data for discussion of the use of within-patient studies instead of parallel-group studies. 4 ' w If we accept from the literature the concept that /3-blockers and diuretics are likely to be equipotent when compared at the appropriate dosages and to have an additive effect, 21 this withinpatient study has been able to provide the expected answer with a minimum number of patients, when clinic or home blood pressure values are used. It has overcome one of the main limitations of this type of methodology: interaction between treatment and period. None of the carryover effects was significant at the 5% level, either at home or at the clinic. After 2 weeks of active treatment and 1 week without treatment, blood pressure at home returned toward its initial level after each of the three treatments.
Made on a short-term basis, these observations do not indicate that blood pressure would increase so rapidly after stopping long-term treatment with diuretics, /3-blockers, or another antihypertensive agent. 22 They only demonstrate that short periods of treatment allowed the successive testing of these antihypertensive drugs in the same patient, without a residual antihypertensive effect of a previously administered diuretic or /3-blocker, or both. As shown in Table 4 , if a carryover effect is allowed for in the statistical analysis, minimal changes are observed in the results. 17 Even a larger have demonstrated in a two-period crossover clinical trial that, when the within-patient correlation is greater than 0.5, the crossover design outperforms the parallel design, provided the residual carryover effect does not exceed the treatment effect. This information is useful for the future planning of such within-patient studies to test antihypertensive drugs. Under the conditions of this trial (i.e., patients who volunteer to participate, one physician in charge of the trial, multiplicity of the blood pressure measurements in a constant environment, washout periods of 2 weeks after 2 weeks of active treatment, statistical risks of a = 5% and /3 = 10%), a difference of 5 mm Hg in diastolic blood pressure can be detected in 27 patients at the clinic (SD = 8) or in 20 patients (SD = 6) if home blood pressure measurements are used. With the number of subjects included in our study, the antihypertensive effect of the drugs was easily demonstrated by comparison with a placebo, but neither clinic blood pressure measurements nor home blood pressure measurements could detect a significant difference between the antihypertensive effects of oxprenolol and the chlorthalidone-triamterene combination. The factors that influence the calculation of the number of subjects necessary for a trial are the expected difference in blood pressure values and the observed variability. The higher the former, and the lower the latter, the fewer subjects are necessary. Because the fall in blood pressure induced by the treatment was more marked at the clinic than at home, the additive effect of a /3-blocker and diuretics was statistically significant when clinic blood pressure was analyzed, whereas it was significant only for systolic blood pressure when home blood pressure was evaluated.
The second conclusion of this study is that similar results are provided, for a given group of patients, by two different methods of blood pressure measurement. As frequently observed, home blood pressure was lower than clinic blood pressure, and this difference is likely to be related to the anxiogenic effect of the visit to the clinic. 7 ' 8 Although this difference between home blood pressure and clinic blood pressure is quite variable, it is less marked when the patients are taking a /3-blocker, alone or in combination, than in the absence of treatment or when taking only a diuretic. This observation could be explained by an effect of /3-blockers on the arousal response that occurs during blood pressure measurements in the clinic. Similarly, in a verapamil study, Gould et al. 7> 8 observed a significantly greater mean reduction of the clinic systolic blood pressure compared with that observed with either intra-arterial or self-recorded pressure. With prazosin, the mean reduction that they observed in systolic pressure measured in the clinic was again greater than that obtained with the other two methods, although not significantly so.
Finally, such a within-patient trial not only offers the possibility of answering a pharmacological question scientifically by analysis of the mean results obtained in a small group of patients, but it can also be used to select the most effective of the three treatments for each subject included in the trial. The comparison of two parallel groups, which is the most frequently used protocol to test antihypertensive drugs, makes it necessary to impose on each patient the treatment to which he or she has been allocated by randomization. Even if he or she was included in the group where the best results are obtained in terms of efficacy or tolerance, the group observation does not imply that the treatment allocated by the initial randomization was the best for him or her. The careful analysis of the blood pressure values obtained in each of die patients included in this trial emphasizes the fact that a blood pressure result obtained in a group of patients does not mean that each patient within the group received the best therapy. According to a patient by patient analysis, all three treatments appeared to be ineffective in three of the 24 patients, despite the absence of problems of compliance. Other drugs, had to be selected for these three patients. For the 21 others, the individualized choice detected those who benefited most from one of the three treatments and allowed, in this group of patients, for a similar fall in blood pressure to that obtained with the combination, but with a minimal number of drugs. However, it is not known if successive application of the same treatments to the same subjects would provide identical falls in blood pressure each time, or if fluctuations of the response to therapy would occur. Therefore, to validate this methodology of individualized therapeutic choice, repeated administration of the same treatment should be tested in an identical study design ('W of 1" trial). 12 This technique for selecting an antihypertensive agent for an individual patient also implies that the long-term effects of treatment are correlated to its short-term effects, which has indeed been demonstrated with /3-blockers and diuretics administered for 2 and 4 weeks. 1324 The conclusion to be drawn from this study is that a double-blind, crossover trial of antihypertensive drugs performed with appropriate precautions (cooperative patients, standardization of blood pressure measurements at home and at the clinic, 2-week treatment periods separated by 2 weeks of placebo administration), has sufficient statistical power to provide an appropriate comparative evaluation of the antihypertensive effects of three different treatments in a group of fewer than 30 patients. In addition, it may offer each patient the opportunity to be treated with a minimum of drugs and by the therapeutic agent that is most effective for him or her, independently of the global evaluation of the results.
